Adaptive Biotechnologies Corporation $ADPT Stock Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 18.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,087,421 shares of the company’s stock after selling 242,435 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.68% of Adaptive Biotechnologies worth $31,426,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ADPT. Mirae Asset Global Investments Co. Ltd. purchased a new position in Adaptive Biotechnologies in the third quarter valued at $236,000. China Universal Asset Management Co. Ltd. raised its position in shares of Adaptive Biotechnologies by 14.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 29,120 shares of the company’s stock worth $838,000 after acquiring an additional 3,649 shares during the period. Gibbs Wealth Management raised its position in shares of Adaptive Biotechnologies by 4.6% in the third quarter. Gibbs Wealth Management now owns 26,900 shares of the company’s stock worth $777,000 after acquiring an additional 1,191 shares during the period. Sterling Capital Management LLC raised its position in shares of Adaptive Biotechnologies by 870.8% in the third quarter. Sterling Capital Management LLC now owns 5,252 shares of the company’s stock worth $152,000 after acquiring an additional 4,711 shares during the period. Finally, Quadrant Capital Group LLC purchased a new stake in shares of Adaptive Biotechnologies during the 3rd quarter worth about $243,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Guggenheim raised their target price on Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. BTIG Research lifted their price target on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. National Bank Financial set a $34.00 price target on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Finally, Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $30.06.

Insider Transactions at Adaptive Biotechnologies

In other news, COO Julie Rubinstein sold 11,881 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $25.47, for a total transaction of $302,609.07. Following the completion of the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at $9,622,616.94. This represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,050,763 shares of company stock worth $26,806,633. Insiders own 5.70% of the company’s stock.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported Q3 earnings of $0.02 per share, versus the consensus estimate of a $0.10 loss, and revenue of $83.9 million, above the $71.6 million expected. Management also said the company reached total-company profitability ahead of expectations. Quarterly results
• Positive Sentiment: Core MRD revenue grew 44%, and Adaptive raised its 2026 MRD revenue outlook to $276 million–$286 million. The company also outlined a target average selling price of $1,700–$1,800, signaling confidence in continued growth of this business. MRD outlook
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 plan and retained a substantial stake. The planned nature of the sales may make them less informative about her outlook, though insider selling can draw investor attention. Insider sale report
• Negative Sentiment: Despite the quarterly beat, revenue was down 10.7% from a year earlier, and the company continued to report a negative net margin. Investors may look for sustained growth and profitability beyond this quarter. Earnings results

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $26.83 on Friday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $30.74. The firm has a market capitalization of $4.28 billion, a PE ratio of -59.62 and a beta of 2.18. The business’s 50 day moving average price is $26.39 and its 200-day moving average price is $19.81.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.12. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $71.57 million. Adaptive Biotechnologies had a negative return on equity of 23.47% and a negative net margin of 23.67%. The firm’s revenue was down 10.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. As a group, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current fiscal year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.